What Is Lifecore Biomedical, Inc. (LFCR) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Lifecore Biomedical, Inc.'s intrinsic value is estimated at $2.35, suggesting the stock is overvalued at its current price of $4.86. With 6 out of 7 models flagging downside (-51.7% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at +11.9% (fair value: $5.44), while First Chicago is the most conservative at -87.4% ($0.61). The spread between these extremes — +99.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About LFCR?
7 of 13 models are currently active for LFCR. Of these, 1 model suggests upside while 6 models suggest overvaluation. See which stocks rank higher →
How Does LFCR Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, LFCR ranks #151 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, Lifecore Biomedical, Inc. competes in an environment where patent cliff exposure often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is LFCR a Value Trap?
CirclFi's Value Trap algorithm assigns LFCR a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Lifecore Biomedical, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Lifecore Biomedical, Inc. is rated at 5.6/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +99.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every LFCR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across LFCR's 7 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad